J Rheumatol 2018 Jan 15. Epub 2018 Jan 15.
From Columbia University Medical Center, New York; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, Maryland, USA. Funding provided by Intramural Research Program, NIAMS, and NIH. RW is a recipient of the Rheumatology Research Foundation Scientist Development Award. The content is the responsibility of the authors and does not necessarily represent the official views of the NIH. Portions of the data were obtained from the Pfizer Clinical Data Set through a data-use agreement, and from Amgen Inc. through a data-sharing agreement. In addition, the study, carried out under YODA Project #2014-0291, used data obtained from the Yale University Open Data Access Project, which has an agreement with Janssen Research & Development LLC. The interpretation and reporting of research using these data are solely the responsibility of the authors and do not necessarily represent the official views of the Yale University Open Data Access Project or Janssen Research & Development LLC. Amgen Inc., Pfizer Inc., and the Yale Open Data Access Project were provided copies of the manuscript before submission. R. Wang, MD, MHS, Division of Rheumatology, Columbia University Medical Center; A. Dasgupta, PhD, Intramural Research Program, NIAMS, NIH; M.M. Ward, MD, MPH, Intramural Research Program, NIAMS. Address correspondence to Dr. R. Wang, MD, MHS, Division of Rheumatology, Columbia University Medical Center, P & S 10-445, 630 W. 168th St., New York, New York 10032, USA. E-mail: Accepted for publication September 29, 2017.
: To compare the efficacy of 6 tumor necrosis factor-α inhibitors (TNFi) in treatment of ankylosing spondylitis (AS) at 12 weeks and 24 weeks.Methods
: We performed a systematic literature review of randomized controlled trials of TNFi in patients with active AS. We included trials that reported efficacy at 10 to 14 weeks (12-week analysis) and at 24 to 30 weeks (24-week analysis). Read More